JP4731324B2 - N−o結合性架橋構造型新規人工核酸 - Google Patents
N−o結合性架橋構造型新規人工核酸 Download PDFInfo
- Publication number
- JP4731324B2 JP4731324B2 JP2005513440A JP2005513440A JP4731324B2 JP 4731324 B2 JP4731324 B2 JP 4731324B2 JP 2005513440 A JP2005513440 A JP 2005513440A JP 2005513440 A JP2005513440 A JP 2005513440A JP 4731324 B2 JP4731324 B2 JP 4731324B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- amino
- nucleic acid
- oxo
- protected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020004707 nucleic acids Proteins 0.000 title claims description 21
- 102000039446 nucleic acids Human genes 0.000 title claims description 21
- 150000007523 nucleic acids Chemical class 0.000 title claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 105
- 125000006239 protecting group Chemical group 0.000 claims abstract description 86
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 24
- 239000002777 nucleoside Substances 0.000 claims abstract description 22
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 21
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 13
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 6
- -1 p-toluenesulfonyl group Chemical group 0.000 claims description 502
- 125000003118 aryl group Chemical group 0.000 claims description 85
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 76
- 125000003277 amino group Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000004432 carbon atom Chemical group C* 0.000 claims description 50
- 125000002252 acyl group Chemical group 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 125000001931 aliphatic group Chemical group 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 17
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical group NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 claims description 10
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 125000005499 phosphonyl group Chemical group 0.000 claims description 6
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical group NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- BBAMTDMNXVSCRU-UHFFFAOYSA-N (4-chlorophenyl) dihydrogen phosphate Chemical group OP(O)(=O)OC1=CC=C(Cl)C=C1 BBAMTDMNXVSCRU-UHFFFAOYSA-N 0.000 claims description 3
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 3
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 36
- 108020004414 DNA Proteins 0.000 abstract description 31
- 230000000692 anti-sense effect Effects 0.000 abstract description 16
- 102000053602 DNA Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- 239000000243 solution Substances 0.000 description 43
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 239000012043 crude product Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Chemical group 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 125000005129 aryl carbonyl group Chemical group 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- 235000017557 sodium bicarbonate Nutrition 0.000 description 19
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000002585 base Substances 0.000 description 17
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000008204 material by function Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 125000004219 purine nucleobase group Chemical group 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000005103 alkyl silyl group Chemical group 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005868 electrolysis reaction Methods 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 4
- 238000006303 photolysis reaction Methods 0.000 description 4
- 230000015843 photosynthesis, light reaction Effects 0.000 description 4
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 3
- 125000006074 1-ethyl-2-butenyl group Chemical group 0.000 description 3
- 125000006075 1-ethyl-3-butenyl group Chemical group 0.000 description 3
- 125000006039 1-hexenyl group Chemical group 0.000 description 3
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 3
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 3
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 3
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 3
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 3
- 125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 3
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 3
- 125000006023 1-pentenyl group Chemical group 0.000 description 3
- 125000006017 1-propenyl group Chemical group 0.000 description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 3
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 3
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 3
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 3
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 description 3
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 3
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
- 125000005916 2-methylpentyl group Chemical group 0.000 description 3
- 125000006024 2-pentenyl group Chemical group 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 3
- 125000006041 3-hexenyl group Chemical group 0.000 description 3
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 3
- 125000006043 5-hexenyl group Chemical group 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- XVZXOLOFWKSDSR-UHFFFAOYSA-N Cc1cc(C)c([C]=O)c(C)c1 Chemical group Cc1cc(C)c([C]=O)c(C)c1 XVZXOLOFWKSDSR-UHFFFAOYSA-N 0.000 description 3
- 108091027757 Deoxyribozyme Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000004849 alkoxymethyl group Chemical group 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229940127073 nucleoside analogue Drugs 0.000 description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 3
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 3
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 2
- 125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 2
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 2
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- 125000006040 2-hexenyl group Chemical group 0.000 description 2
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 2
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 2
- 125000004924 2-naphthylethyl group Chemical group C1=C(C=CC2=CC=CC=C12)CC* 0.000 description 2
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 2
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 2
- 125000006042 4-hexenyl group Chemical group 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 150000001868 cobalt Chemical class 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000005332 diethylamines Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZXSSXAUYKUTLBP-UHFFFAOYSA-N hexane;trichloroborane Chemical compound ClB(Cl)Cl.CCCCCC ZXSSXAUYKUTLBP-UHFFFAOYSA-N 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002815 nickel Chemical class 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000008300 phosphoramidites Chemical group 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 159000000000 sodium salts Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- YUDSCJBUWTYENI-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O YUDSCJBUWTYENI-VPCXQMTMSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
- ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical group ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DDYAZDRFUVZBMM-UHFFFAOYSA-N chloro-[chloro-di(propan-2-yl)silyl]oxy-di(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)O[Si](Cl)(C(C)C)C(C)C DDYAZDRFUVZBMM-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WLOLJOODDKFZEJ-UHFFFAOYSA-N methanol;4-methylbenzenesulfonate;pyridin-1-ium Chemical compound OC.C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 WLOLJOODDKFZEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004712 n-pentylthio group Chemical group C(CCCC)S* 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(1)相補なRNA鎖に対する二重鎖形成能が非常に高い。
(2)また、2’,4’−BNANC修飾DNAオリゴヌクレオチドは二本鎖DNA鎖に対する三重鎖形成能にも卓越している。
(3)ヌクレアーゼ耐性が抜群である。
(4)本発明の人工核酸2’,4’−BNANC分子中に含まれるN−O結合は還元試薬により緩和な条件下で選択的に開裂することができ、NH基とOH基が遊離する。このNH基やOH基を足掛かりに別機能性分子を結合させることで、オリゴヌクレオチド類縁体調製の前後を問わず、様々な複合体(コンジュゲート体)を得ることが容易である。別機能性分子としては、蛍光分子や化学発光分子や放射性同位原子を含む分子種などの標識用分子、様々なDNA(RNA)切断活性分子、細胞内や核内移行シグナルペプチド類等々、が可能である。
本発明のオリゴヌクレオチド類縁体は、下記一般式(II)で表されるヌクレオシド類縁体の単位構造のいずれか1種以上を1または2個以上含有するDNAオリゴヌクレオチド又はRNAオリゴヌクレオチド類縁体またはその薬理学上許容される塩である。但し、これら構造の1種以上を2個以上含有する場合は、当該構造間でBaseは同一または異なっていても良い。また、オリゴヌクレオチド類縁体中の各ヌクレオシド間の結合は、天然核酸と同じリン酸ジエステル結合[−OP(O2 −)O−]以外にホスホロチオアート結合[−OP(O)(S−)O−]を1又は2個以上含有していても良い。
一般式(I)及び(II)中、Baseの芳香族複素環基とは、炭化水素環の構成原子である炭素原子を、1個以上の窒素原子、硫黄原子もしくは酸素原子などのヘテロ原子に置き換えた構造を有し、芳香族性を示す5〜20員環のあらゆる基をいい、単環、縮合環を含む。具体的には、例えば、ピリミジンもしくはプリン核酸塩基、以下のα群から選択される置換基を1つ以上有していてもよいピリミジンもしくはプリン核酸塩基が挙げられる。ここで、ピリミジンもしくはプリン核酸塩基には、核酸の構成成分として一般に知られる塩基(例えば、グアニン、アデニン、シトシン、チミン、ウラシル)、及びその他これらに類する核酸成分の塩基として作用もしくは代用し得るあらゆる化学構造が含まれる。その他、チオフェン、チアントレン、フラン、ピラン、イソベンゾフラン、クロメン、キサンテン、フェノキサチイン、ピロール、イミダゾール、ピラゾール、イソチアゾール、イソキサゾール、ピリダジン、インドリジン、インドール、イソインドール、イソキノリン、キノリン、ナフチリジン、キノキサリン、キナゾリン、プテリジン、カルバゾール、フェナントリジン、アクリジン、ペリミジン、フェナジン、フェナルサジン、フェノチアジン、フラザン、フェノキサジン、ピロリジン、ピロリン、イミダゾリジン、イミダゾリン、ピラゾリジンなども含まれる。好適には、ピリミジンもしくはプリン核酸塩基、以下のα群から選択される置換基を1つ以上有していてもよいピリミジンもしくはプリン核酸塩基であり、具体的には、プリン−9−イル基、2−オキソ−ピリミジン−1−イル基、または下記α群から選択される置換基を有するプリン−9−イル基もしくは2−オキソ−ピリミジン−1−イル基が好適である。
(1)R1が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、またはシリル基である化合物及びその塩、
(2)R1が、水素原子、アセチル基、ベンゾイル基、メタンスルホニル基、p−トルエンスルホニル基、ベンジル基、p−メトキシベンジル基、トリチル基、ジメトキシトリチル基、モノメトキシトリチル基又はtert−ブチルジフェニルシリル基である化合物及びその塩、
(3)R2が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、シリル基、ホスホロアミダイト基、ホスホニル基、リン酸基または核酸合成の保護基で保護されたリン酸基である化合物及びその塩、
(4)R2が、水素原子、アセチル基、ベンゾイル基、メタンスルホニル基、p−トルエンスルホニル基、ベンジル基、p−メトキシベンジル基、tert−ブチルジフェニルシリル基、−P(OC2H4CN)(N(i−Pr)2)、−P(OCH3)(N(i−Pr)2)、ホスホニル基、又は、2−クロロフェニルもしくは4−クロロフェニルリン酸基である化合物およびその塩、
(5)R3が、水素原子、炭素数1〜5のアルキル基、炭素数1〜5のアルケニル基、炭素数6〜14のアリール基、1〜3個のアリール基で置換されたメチル基、メタンスルホニル基やp−トルエンスルホニル基などの低級脂肪族あるいは芳香族スルホニル基又はアセチル基などの炭素数1〜5の脂肪族アシル基やフェノキシアセチル基およびベンゾイル基などの芳香族アシル基である化合物およびその塩、また、R3の機能性分子ユニット置換基が、蛍光あるいは化学発光標識分子、核酸切断活性官能基、又は細胞内若しくは核内移行シグナルペプチドである請求項1〜6のいずれか1項に記載の化合物及びその塩、
(6)Baseが、6−アミノプリン−9−イル(即ち、アデニニル)、アミノ基が核酸合成の保護基で保護された6−アミノプリン−9−イル、2,6−ジアミノプリン−9−イル、2−アミノ−6−クロロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−クロロプリン−9−イル、2−アミノ−6−フルオロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−フルオロプリン−9−イル、2−アミノ−6−ブロモプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ブロモプリン−9−イル、2−アミノ−6−ヒドロキシプリン−9−イル(即ち、グアニニル)、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ヒドロキシプリン−9−イル、6−アミノ−2−メトキシプリン−9−イル、6−アミノ−2−クロロプリン−9−イル、6−アミノ−2−フルオロプリン−9−イル、2,6−ジメトキシプリン−9−イル、2,6−ジクロロプリン−9−イル、6−メルカプトプリン−9−イル、2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル(即ち、シトシニル)、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、4−アミノ−2−オキソ−5−クロロ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メトキシ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メルカプト−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−ヒドロキシ−1,2−ジヒドロピリミジン−1−イル(即ち、ウラシニル)、2−オキソ−4−ヒドロキシ−5−メチル−1,2−ジヒドロピリミジン−1−イル(即ち、チミニル)、4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イル(即ち、5−メチルシトシニル)基、または、アミノ基が核酸合成の保護基で保護された4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イルである化合物及びその塩、
(7)Baseが、ベンゾイルアミノプリン−9−イル、アデニル、2−イソブチリルアミノ−6−ヒドロキシプリン−9−イル、グアニニル、2−オキソ−4−ベンゾイルアミノ−1,2−ジヒドロピリミジン−1−イル、シトシニル、2−オキソ−5−メチル−4−ベンゾイルアミノ−1,2−ジヒドロピリミジン−1−イル、5−メチルシトシニル、ウラシニル又はチミニル基である化合物及びその塩を挙げることができる。
(8)R3が、水素原子、炭素数1〜5のアルキル基、ベンジル基などのアラルキル基、アセチル基やベンゾイル基などの低級脂肪族あるいは芳香族アシル基、メタンスルホニル基やp−トルエンスルホニル基などの脂肪族あるいは芳香族スルホニル基であるオリゴヌクレオチド類縁体及びその薬理学上許容される塩、
(9)Baseが、6−アミノプリン−9−イル(即ち、アデニニル)、アミノ基が核酸合成の保護基で保護された6−アミノプリン−9−イル、2,6−ジアミノプリン−9−イル、2−アミノ−6−クロロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−クロロプリン−9−イル、2−アミノ−6−フルオロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−フルオロプリン−9−イル、2−アミノ−6−ブロモプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ブロモプリン−9−イル、2−アミノ−6−ヒドロキシプリン−9−イル(即ち、グアニニル)、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ヒドロキシプリン−9−イル、6−アミノ−2−メトキシプリン−9−イル、6−アミノ−2−クロロプリン−9−イル、6−アミノ−2−フルオロプリン−9−イル、2,6−ジメトキシプリン−9−イル、2,6−ジクロロプリン−9−イル、6−メルカプトプリン−9−イル、2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル(即ち、シトシニル)、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、4−アミノ−2−オキソ−5−クロロ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メトキシ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メルカプト−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−ヒドロキシ−1,2−ジヒドロピリミジン−1−イル(即ち、ウラシニル)、2−オキソ−4−ヒドロキシ−5−メチル−1,2−ジヒドロピリミジン−1−イル(即ち、チミニル)、4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イル(即ち、5−メチルシトシニル)基、または、アミノ基が核酸合成の保護基で保護された4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イルであるオリゴヌクレオチド類縁体及びその薬理学上許容される塩、
(10)Baseが、ベンゾイルアミノプリン−9−イル、アデニル、2−イソブチリルアミノ−6−ヒドロキシプリン−9−イル、グアニニル、2−オキソ−4−ベンゾイルアミノ−1,2−ジヒドロピリミジン−1−イル、シトシニル、2−オキソ−5−メチル−4−ベンゾイルアミノ−1,2−ジヒドロピリミジン−1−イル、5−メチルシトシニル、ウラシニル又はチミニル基であるオリゴヌクレオチド類縁体及びその薬理学上許容される塩を挙げることができる。
(1)ヌクレオシド類縁体の合成
一般式(I)で表される化合物は、実施例に記載の方法および本分野の従来技術に基づいて合成できる。反応条件、保護基導入試薬、反応試薬は、具体的には実施例に記載の方法を参考にすることができるが、これに限定されず、本分野の技術常識に基づき使用可能な反応条件、試薬を適宜採用することができる。例えば、特開2000−297097号公報、特開平10−304889号公報に記載の方法を参考にすることができる。また、一般式(I)または(II)におけるBaseとして種々の天然、非天然の核酸塩基およびその他の芳香族複素環や芳香族炭化水素環を有する場合についても、特開平10−304889号公報に記載の方法を参考にして、本発明化合物の原料を合成することができる。
(2)オリゴヌクレオチド類縁体の合成
本発明のヌクレオシド類縁体を含むオリゴヌクレオチド類縁体は、公知のDNAシンセサイザーを用いて種々合成することができる。次いで、得られるオリゴヌクレオチド類縁体を逆相カラムを用いて精製し、生成物の純度を逆相HPLCやMALDI−TOF−MSで分析することにより、精製オリゴヌクレオチド類縁体の生成を確認できる。
本発明のヌクレオシド類縁体は、オリゴヌクレオチド類縁体の中に1個以上存在させることができる。また、オリゴヌクレオチド類縁体の2カ所以上の位置に、1又は2以上の天然ヌクレオチドを介して隔離された状態で存在させてもよい。本発明によれば、本発明のヌクレオシド類縁体を必要な位置に必要な数(長さ)で導入したオリゴヌクレオチド類縁体を合成することができる。オリゴヌクレオチド類縁体全体の長さとしてヌクレオチド単位が2〜50、好ましくは8〜30個である。
[実施例1]ヌクレオシド類縁体(2’,4’−BNANCアミダイト体)の合成
(1)化合物2の合成
前記の合成スキームに示す化合物1(49mg,0.073mmol)のテトラヒドロフラン溶液(3.5ml)に氷冷下、40%メチルアミン水溶液(0.11ml,1.50mmol)を加え、室温で3時間撹拌した。反応溶液の溶媒を留去した後、酢酸エチルで抽出し、有機層を水、飽和食塩水で洗浄した。有機層を無水硫酸ナトリウムで乾燥し、溶媒留去後、シリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=1:1)により精製し、化合物2(45mg,99%)を白色固体として得た。
窒素気流下、化合物2(146mg,0.23mmol)のピリジン溶液(1.5ml)に氷冷下、塩化メチルスルホニル(45(1,0.59mmol)を加え、室温で1時間撹拌した。反応溶液に水を加え、酢酸エチルで抽出し、有機層を飽和重曹水、飽和食塩水で洗浄後、無水硫酸ナトリウムにて乾燥した。溶媒を減圧留去し、得られた粗成績体3(170mg)は精製せず、次の反応に用いた。
前反応で得られた粗成績体3(170mg)の水−エタノール溶液(1:2,6ml)に、室温で1M水酸化ナトリウム水溶液(0.70ml,0.70mmol)を加え、1時間撹拌した。10%塩酸水溶液で中和後、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=15:1)により精製し、化合物4(139mg,95% from 2 in 2 steps)を白色固体として得た。
窒素気流下、化合物4(0.80g,1.28mmol)のエタノール溶液(10ml)に、20%水酸化パラジウム−炭素粉末(0.60g)、シクロヘキセン(5.2ml,51mmol)を加え、5時間加熱還流した。さらに水酸化パラジウム−炭素粉末(0.20g)を加え、17時間加熱還流した。反応溶液を濾過した後、溶媒を減圧留去した。得られた粗成績体5(0.46g)は、精製せず次の反応に用いた。
窒素気流下、化合物5(0.46g)のN,N−ジメチルホルムアミド溶液(10ml)に、1,3−ジクロロ−1,1,3,3−テトライソプロピルジシロキサン(0.45ml,1.41mmol)、イミダゾール(0.38g,5.63mmol)を加え、室温にて5時間撹拌した。反応液をエーテルで抽出し、有機層を水、飽和食塩水で洗浄した後、硫酸マグネシウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=2:1→1:1)により精製し、化合物6(0.60g,68% from 4 in 2 steps)を白色固体として得た。
窒素気流下、化合物6(200mg,0.29mmol)のピリジン溶液(3ml)に氷冷下、無水トリフルオロメタンスルホン酸(0.15ml,0.88mmol)、4−(ジメチルアミノ)ピリジン(7mg,0.06mmol)を加え、室温で7.5時間撹拌した。反応溶液に水を加え、ジクロロメタンで抽出した。有機層を飽和重曹水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体7(0.29g)を精製せず、次の反応に用いた。
窒素気流下、前反応で得られた粗成績体7(0.29g)のアセトニトリル溶液(3ml)に、室温でN−ヒドロキシフタルイミド(67mg,0.41mmol)、1,8−ジアザビシクロ[5.4.0]−7−ウンデセン(61(1,0.41mmol)を加え、室温で12時間撹拌した。反応溶液をジクロロメタンで抽出し、有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム)により精製し、化合物8(0.15g,61% from 6 in 2 steps)を黄色固体として得た。
化合物8(1.16g,1.40mmol)のエタノール溶液(35ml)に、ヒドラジン−水和物(0.12ml,2.38mmol)を加え、室温で10分間撹拌した。反応溶液の溶媒を留去した後、濾過し、濾液を酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、得られた粗成績体9(0.93g)は精製せず、次の反応に用いた。
窒素気流下、前反応で得られた粗成績体9(0.93g)の塩化メチレン溶液(15ml)に氷冷下、飽和重曹水(4.0ml,4.2mmol)、クロロギ酸ベンジル(0.30ml,2.1mmol)を加え、1時間撹拌した。反応溶液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄し、硫酸マグネシウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=4:1)により精製し、化合物10(0.92g,94% from 8 in 2 steps)を白色固体として得た。
窒素気流下、水素化ナトリウム(60% in oil,0.55g,13.7mmol)のテトラヒドロフラン懸濁液(25ml)に氷冷下、化合物10(3.81g,4.57mmol)のテトラヒドロフラン溶液(15ml)を滴下し、1時間撹拌した後、室温で5時間撹拌した。飽和シュウ酸水溶液で中和後、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム→クロロホルム:メタノール=100:1)により精製し、化合物11(2.87g,95%)を白色固体として得た。
窒素気流下、前反応で得られた粗成績体11(0.35mg,0.53mmol)の塩化メチレン溶液(10ml)に氷冷下、1M三塩化ホウ素ヘキサン溶液(5.29ml,5.29mmol)を加え、1時間撹拌した。反応溶液に飽和重曹水を加え、酢酸エチルで抽出し、有機層を水、飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=50:1)により精製し、化合物12(0.27g,96%)を白色固体として得た。
化合物12(0.19g,0.36mmol)の1M p−トルエンスルホン酸ピリジニウム−メタノール溶液(3.6ml)に、室温にて20%ホルムアルデヒド水溶液(0.06ml,0.40mmol)を加え、10分間撹拌した。さらに、氷冷下シアン化水素化ホウ素ナトリウム(45mg,0.72mmol)を加え、1時間撹拌した。反応溶液を酢酸エチルで抽出し、水、飽和重曹水、飽和食塩水で洗浄し、有機層を無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=2:1)にて精製し、化合物13(0.19g,100%)を白色固体として得た。
化合物13(46mg,0.085mmol)のテトラヒドロフラン溶液(2ml)にフッ化テトラ−n−ブチルアンモニウム(1M inテトラヒドロフラン,0.17ml,0.17mmol)を加え、室温で5分間撹拌した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(酢酸エチル:メタノール=15:1)により精製し、化合物14(25mg,100%)を白色固体として得た。
化合物14(0.16g,0.54mmol)のピリジン溶液(10ml)に塩化4,4’−ジメトキシトリチル(0.22g,0.64mmol)を加え、室温で12時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出し、有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n−ヘキサン:酢酸エチル=1:2→酢酸エチル:メタノール=30:1)にて精製し、化合物15(0.30g,93%)を白色固体として得た。
化合物15(0.17g,0.28mmol)及び4,5−ジシアノイミダゾール(40mg,0.34mmol)のアセトニトリル溶液(6ml)に、2−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロアミダイト(0.13ml,0.42mmol)を加え、室温で4時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和重曹水、水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n−ヘキサン:酢酸エチル=1:1)、ついで再沈澱(酢酸エチル−ヘキサン)により精製し、化合物16(0.20g,88%)を白色固体として得た。
窒素気流下、1,2,4,−トリアゾール(278mg,4.03mmol)のアセトニトリル懸濁液(9ml)に、氷冷下、塩化ホスホリル(86ml,0.92mmol)を加え10分間激しく撹拌し、さらにトリエチルアミン(0.64ml,4.62mmol)を加え35分間撹拌した。氷冷下、化合物16(95mg,0.12mmol)のアセトニトリル溶液(3ml)を加え、5.5時間撹拌した後、室温でさらに2.5時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=1:2)、ついで再沈澱(酢酸エチル−ヘキサン)により精製し、化合物17(83mg,83%)を白色固体として得た。
化合物12(100mg,0.19mmol)およびトリエチルアミン(32ml,0.12mmol)の塩化メチレン溶液(3ml)に、氷冷下、塩化フェノキシアセチル(29ml,0.21mmol)を加え30分間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=2:1)により精製し、化合物18(115mg,92%)を白色固体として得た。
窒素気流下、室温で化合物18(0.34g,0.51mmol)のテトラヒドロフラン溶液(10ml)にフッ化テトラn−ブチルアンモニウム(1Mテトラヒドロフラン溶液,1.0ml,1.0mmol)を加え、5分間撹拌した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(酢酸エチル:メタノール=15:1)により精製し、化合物19(0.20g,95%)を白色固体として得た。
窒素気流下、室温で化合物19(0.17g,0.41mmol)のピリジン溶液(8ml)に塩化4,4’−ジメトキシトリチル(0.25g,0.73mmol)を加え、7時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n−ヘキサン:酢酸エチル=1:1→酢酸エチル:メタノール=50:1)により精製し、化合物20(0.25g,86%)を白色固体として得た。
化合物20(0.25g,0.35mmol)及び4,5−ジシアノイミダゾール(41mg,0.35mmol)のアセトニトリル溶液(7ml)に、2−シアノエチル−N,N,N’,N’−テトライソプロピルホスホロアミダイト(0.13ml,0.42mmol)を加え、室温で3時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和重曹水、水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n−ヘキサン:酢酸エチル=1:1)、ついで再沈澱(酢酸エチル−ヘキサン)により精製し、化合物21(0.27g,85%)を白色固体として得た。
窒素気流下、1,2,4,−トリアゾール(229mg,3.32mmol)のアセトニトリル懸濁液(10ml)に、氷冷下、塩化ホスホリル(71ml,0.76mmol)を加え10分間激しく撹拌し、さらにトリエチルアミン(0.53ml,3.81mmol)を加え35分間撹拌した。氷冷下、化合物21(90mg,0.10mmol)のアセトニトリル溶液(2ml)を加え、5時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体を再沈澱(酢酸エチル−ヘキサン)により精製し、化合物22(90mg,95%)を白色固体として得た。
窒素気流下、1,2,4,−トリアゾール(1.41g,20.4mmol)のアセトニトリル懸濁液(61ml)に、氷冷下、塩化ホスホリル(0.44ml,4.67mmol)を加え10分間激しく撹拌し、さらにトリエチルアミン(3.27ml,23.4mmol)を加え35分間撹拌した。氷冷下、化合物11(409mg,0.62mmol)のアセトニトリル溶液(3ml)を加え、2時間撹拌した後、室温でさらに3時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体23(497mg)は精製せず、次の反応に用いた。
化合物23(497mg)の1,4−ジオキサン溶液(10.6ml)に、室温で28%アンモニア水溶液(1.76ml)を加え、2時間撹拌した。溶媒を減圧流去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=30:1)により精製し、化合物24(343mg,84% from 11 in 2 steps)を白色固体として得た。
化合物24(175mg,0.26mmol)の塩化メチレン溶液(2.6ml)に、氷冷下、飽和重曹水(0.8ml,0.79mmol)と塩化ベンゾイル(92ml,0.79mmol)を加え、2時間撹拌した後、室温でさらに1.5時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(クロロホルム)により精製し、化合物25(161mg,80%)を白色固体として得た。
窒素気流下、化合物25(115mg,0.15mmol)の塩化メチレン溶液(7.5ml)に、−78℃冷却下、1M三塩化ホウ素ヘキサン溶液(1.35ml,1.35mmol)を加え、1.5時間撹拌し、氷冷下でさらに2.5時間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体26(90mg)は精製せず、次の反応に用いた。
窒素気流下、化合物26(90mg)とトリエチルアミン(25ml,0.18mmol)の塩化メチレン溶液(1.5ml)に、氷冷下、塩化フェノキシアセチル(23ml,0.17mmol)を加え45分間撹拌した。反応液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=2:1)により精製し、化合物27(49mg,42% from 23 in 2 steps)を白色固体として得た。
窒素気流下、室温で化合物27(45mg,0.06mmol)のテトラヒドロフラン溶液(1.2ml)に、フッ化テトラn−ブチルアンモニウム(1Mテトラヒドロフラン溶液,0.12ml,0.12mmol)を加え、10分間撹拌した。溶媒を減圧留去し、得られた粗成績体をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=1:1)により精製し、化合物28(31mg,100%)を白色固体として得た。
(1)2’,4’−BNANC修飾オリゴヌクレオチドの合成
2’,4’−BNANCモノマーユニットを含有するオリゴヌクレオチド類縁体(1)〜(22)は、標準的なホスホロアミダイトプロトコールに従って、核酸自動合成機ExpediteTM 8909(ABI社製)により0.2mmolスケールで合成した。アミダイトと5’−末端の水酸基とのカップリング時間は、天然のヌクレオシドアミダイトでは94秒、2’,4’−BNANCアミダイト(16、17および21)では300秒に設定した。
実施例で合成したオリゴヌクレオチド類縁体(1)〜(5)および(13)〜(17)(アンチセンス鎖)と天然DNAあるいはRNAオリゴヌクレオチドのセンス鎖とをアニーリング処理したものの融解温度(Tm)を測定することにより、アンチセンス鎖の二重鎖形成能を調べた。
[実験例2]2’,4’−BNANC修飾オリゴヌクレオチドのTm測定(三重鎖形成能評価)
実施例で合成したオリゴヌクレオチド類縁体(6)〜(11)および(18)〜(21)について、実験例1と同様の方法により、下記の標的2本鎖DNAとの三重鎖形成能を調べた。測定の際の塩濃度やpHについては各表の下に記載してある条件を用いた。
実験例3:酵素耐性の測定
天然型(DNAオリゴヌクレオチド)及び非天然型の下記のオリゴヌクレオチドについて、オリゴヌクレオチドを3’側から分解するエキソヌクレアーゼに対する耐性を調べた。
HPLCによる各オリゴヌクレオチド類の残存率の経時変化を表6及び図1に示した。
Claims (18)
- 下記一般式(I)で表される化合物及びその塩。
(式中、Baseは、置換基を有していてもよい芳香族複素環基もしくは芳香族炭化水素環基を示す。
R1、R2は、同一又は異なって、水素原子、核酸合成の水酸基の保護基、アルキル基、アルケニル基、シクロアルキル基、アリール基、アラルキル基、アシル基、スルホニル基、シリル基、リン酸基、核酸合成の保護基で保護されたリン酸基、または、−P(R4)R5[式中、R4及びR5は、同一または異なって、水酸基、核酸合成の保護基で保護された水酸基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、アミノ基、炭素数1〜5のアルコキシ基、炭素数1〜5のアルキルチオ基、炭素数1〜6のシアノアルコキシ基、または、炭素数1〜5のアルキル基で置換されたアミノ基を示す。]を示す。
R3は、水素原子、アルキル基、アルケニル基、シクロアルキル基、アリール基、アラルキル基、アシル基、スルホニル基、及び細胞内若しくは核内移行シグナルペプチドを示す。
mは、0〜2の整数、及びnは、1〜3の整数である。) - R1が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、または、シリル基である、請求項1に記載の化合物及びその塩。
- R1が、水素原子、アセチル基、ベンゾイル基、メタンスルホニル基、p−トルエンスルホニル基、ベンジル基、p−メトキシベンジル基、トリチル基、ジメトキシトリチル基、モノメトキシトリチル基、または、tert−ブチルジフェニルシリル基である、請求項1に記載の化合物及びその塩。
- R2が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、シリル基、ホスホロアミダイト基、ホスホニル基、リン酸基、または、核酸合成の保護基で保護されたリン酸基である、請求項1〜3のいずれか1項に記載の化合物及びその塩。
- R2が、水素原子、アセチル基、ベンゾイル基、メタンスルホニル基、p−トルエンスルホニル基、ベンジル基、p−メトキシベンジル基、tert−ブチルジフェニルシリル基、−P(OC2H4CN)(N(i−Pr)2)、−P(OCH3)(N(i−Pr)2)、ホスホニル基、または、2−クロロフェニルもしくは4−クロロフェニルリン酸基である、請求項1〜3のいずれか1項に記載の化合物及びその塩。
- R3が、水素原子、フェノキシアセチル基、炭素数1〜5のアルキル基、炭素数1〜5のアルケニル基、炭素数6〜14のアリール基、1〜3個のアリール基で置換されたメチル基、メタンスルホニル基やp−トルエンスルホニル基などの低級脂肪族あるいは芳香族スルホニル基又はアセチル基などの炭素数1〜5の脂肪族アシル基やベンゾイル基などの芳香族アシル基である請求項1〜5のいずれか1項に記載の化合物及びその塩。
- Baseが、プリン−9−イル基、2−オキソ−ピリミジン−1−イル基、または下記α群から選択される置換基を有するプリン−9−イル基もしくは2−オキソ−ピリミジン−1−イル基である、請求項1〜6のいずれか1項に記載の化合物及びその塩。
α群:水酸基、核酸合成の保護基で保護された水酸基、炭素数1〜5のアルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1〜5のアルキルチオ基、アミノ基、核酸合成の保護基で保護されたアミノ基、炭素数1〜5のアルキル基で置換されたアミノ基、炭素数1〜5のアルキル基、および、ハロゲン原子。 - Baseが、6−アミノプリン−9−イル(即ち、アデニニル)、アミノ基が核酸合成の保護基で保護された6−アミノプリン−9−イル、2,6−ジアミノプリン−9−イル、2−アミノ−6−クロロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−クロロプリン−9−イル、2−アミノ−6−フルオロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−フルオロプリン−9−イル、2−アミノ−6−ブロモプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ブロモプリン−9−イル、2−アミノ−6−ヒドロキシプリン−9−イル(即ち、グアニニル)、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ヒドロキシプリン−9−イル、6−アミノ−2−メトキシプリン−9−イル、6−アミノ−2−クロロプリン−9−イル、6−アミノ−2−フルオロプリン−9−イル、2,6−ジメトキシプリン−9−イル、2,6−ジクロロプリン−9−イル、6−メルカプトプリン−9−イル、2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル(即ち、シトシニル)、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、4−アミノ−2−オキソ−5−クロロ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メトキシ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メルカプト−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−ヒドロキシ−1,2−ジヒドロピリミジン−1−イル(即ち、ウラシニル)、2−オキソ−4−ヒドロキシ−5−メチル−1,2−ジヒドロピリミジン−1−イル(即ち、チミニル)、4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イル(即ち、5−メチルシトシニル)、または、アミノ基が核酸合成の保護基で保護された4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イルである、請求項1〜7のいずれか1項に記載の化合物及びその塩。
- mが0であり、nが1である、請求項1〜8のいずれか1項に記載の化合物及びその塩。
- 下記一般式(II)で表されるヌクレオシドの単位構造の1種以上を1または2個以上含有するDNAオリゴヌクレオチド又はRNAオリゴヌクレオチドとしてのオリゴヌクレオチドまたはその薬理学上許容される塩。
但し、オリゴヌクレオチド中の各ヌクレオシド間の結合形態は、天然核酸と同じリン酸ジエステル結合[−OP(O2 −)O−]以外にホスホロチオアート結合[−OP(O)(S−)O−]を1又は2個以上含有していてもよく、また、前記の構造の1種以上を2個以上含有する場合は、当該構造間でBaseは同一または異なることができる。
(式中、Baseは、置換基を有していてもよい芳香族複素環基もしくは芳香族炭化水素環基を示す。
R3は、水素原子、アルキル基、アルケニル基、シクロアルキル基、アリール基、アラルキル基、アシル基、スルホニル基、シリル基、及び細胞内若しくは核内移行シグナルペプチドを示す。
mは、0〜2の整数、及びnは、1〜3の整数である。 - R1が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、または、シリル基である、請求項10に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- R1が、水素原子、アセチル基、ベンゾイル基、メタンスルホニル基、p−トルエンスルホニル基、ベンジル基、p−メトキシベンジル基、トリチル基、ジメトキシトリチル基、モノメトキシトリチル基、または、tert−ブチルジフェニルシリル基である、請求項10に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- R2が、水素原子、脂肪族アシル基、芳香族アシル基、脂肪族あるいは芳香族スルホニル基、1〜3個のアリール基で置換されたメチル基、低級アルキル、低級アルコキシ、ハロゲンもしくはシアノ基でアリール環が置換された1〜3個のアリール基で置換されたメチル基、シリル基、ホスホロアミダイト基、ホスホニル基、リン酸基、または、核酸合成の保護基で保護されたリン酸基である、請求項10〜12のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- R2が、水素原子、アセチル基、ベンゾイル基、ベンジル基、p−メトキシベンジル基、メタンスルホニル基、p−トルエンスルホニル基、tert−ブチルジフェニルシリル基、−P(OC2H4CN)(N(i−Pr)2)、−P(OCH3)(N(i−Pr)2)、ホスホニル基、または、2−クロロフェニルもしくは4−クロロフェニルリン酸基である、請求項10〜12のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- R3が、水素原子、フェノキシアセチル基、炭素数1〜5のアルキル基、炭素数1〜5のアルケニル基、炭素数6〜14のアリール基、1〜3個のアリール基で置換されたメチル基、メタンスルホニル基やp−トルエンスルホニル基などの低級脂肪族あるいは芳香族スルホニル基又はアセチル基などの炭素数1〜5の脂肪族アシル基やベンゾイル基などの芳香族アシル基である、請求項10〜14のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- Baseが、プリン−9−イル基、2−オキソ−ピリミジン−1−イル基、または下記α群から選択される置換基を有するプリン−9−イル基もしくは2−オキソ−ピリミジン−1−イル基である、請求項10〜15のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
α群:水酸基、核酸合成の保護基で保護された水酸基、炭素数1〜5のアルコキシ基、メルカプト基、核酸合成の保護基で保護されたメルカプト基、炭素数1〜5のアルキルチオ基、アミノ基、核酸合成の保護基で保護されたアミノ基、炭素数1〜5のアルキル基で置換されたアミノ基、炭素数1〜5のアルキル基、および、ハロゲン原子。 - Baseが、6−アミノプリン−9−イル(即ち、アデニニル)、アミノ基が核酸合成の保護基で保護された6−アミノプリン−9−イル、2,6−ジアミノプリン−9−イル、2−アミノ−6−クロロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−クロロプリン−9−イル、2−アミノ−6−フルオロプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−フルオロプリン−9−イル、2−アミノ−6−ブロモプリン−9−イル、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ブロモプリン−9−イル、2−アミノ−6−ヒドロキシプリン−9−イル(即ち、グアニニル)、アミノ基が核酸合成の保護基で保護された2−アミノ−6−ヒドロキシプリン−9−イル、6−アミノ−2−メトキシプリン−9−イル、6−アミノ−2−クロロプリン−9−イル、6−アミノ−2−フルオロプリン−9−イル、2,6−ジメトキシプリン−9−イル、2,6−ジクロロプリン−9−イル、6−メルカプトプリン−9−イル、2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル(即ち、シトシニル)、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、アミノ基が核酸合成の保護基で保護された2−オキソ−4−アミノ−5−フルオロ−1,2−ジヒドロピリミジン−1−イル、4−アミノ−2−オキソ−5−クロロ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メトキシ−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−メルカプト−1,2−ジヒドロピリミジン−1−イル、2−オキソ−4−ヒドロキシ−1,2−ジヒドロピリミジン−1−イル(即ち、ウラシニル)、2−オキソ−4−ヒドロキシ−5−メチル−1,2−ジヒドロピリミジン−1−イル(即ち、チミニル)、4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イル(即ち、5−メチルシトシニル)、または、アミノ基が核酸合成の保護基で保護された4−アミノ−5−メチル−2−オキソ−1,2−ジヒドロピリミジン−1−イルである、請求項10〜16のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
- mが0であり、nが1である、請求項10〜17のいずれか1項に記載のオリゴヌクレオチドまたはその薬理学上許容される塩。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005513440A JP4731324B2 (ja) | 2003-08-28 | 2004-08-25 | N−o結合性架橋構造型新規人工核酸 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003304847 | 2003-08-28 | ||
| JP2003304847 | 2003-08-28 | ||
| PCT/JP2004/012173 WO2005021570A1 (ja) | 2003-08-28 | 2004-08-25 | N−0結合性架橋構造型新規人工核酸 |
| JP2005513440A JP4731324B2 (ja) | 2003-08-28 | 2004-08-25 | N−o結合性架橋構造型新規人工核酸 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2005021570A1 JPWO2005021570A1 (ja) | 2007-11-01 |
| JP4731324B2 true JP4731324B2 (ja) | 2011-07-20 |
Family
ID=34269280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005513440A Expired - Lifetime JP4731324B2 (ja) | 2003-08-28 | 2004-08-25 | N−o結合性架橋構造型新規人工核酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7427672B2 (ja) |
| EP (1) | EP1661905B9 (ja) |
| JP (1) | JP4731324B2 (ja) |
| AT (1) | ATE555118T1 (ja) |
| DK (1) | DK1661905T3 (ja) |
| ES (1) | ES2382807T3 (ja) |
| WO (1) | WO2005021570A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014051076A1 (ja) | 2012-09-28 | 2014-04-03 | 株式会社Bna | Bnaクランプ法 |
| WO2018169063A1 (ja) | 2017-03-17 | 2018-09-20 | 国立大学法人千葉大学 | 構造強化されたS-TuDを用いた新規がん治療法 |
Families Citing this family (573)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005042073B4 (de) * | 2005-08-31 | 2010-11-11 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Faserlaser |
| WO2007131237A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of ptp1b |
| EP2527442A3 (en) | 2006-05-05 | 2013-03-06 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| CA2667055C (en) | 2006-10-18 | 2017-05-09 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EP2453016A1 (en) * | 2006-11-27 | 2012-05-16 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EP2188298B1 (en) | 2007-08-15 | 2013-09-18 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
| US20110059895A1 (en) | 2007-11-09 | 2011-03-10 | Isis Pharmaceuticals, Inc. | Modulation of factor 9 expression |
| KR20100105550A (ko) | 2007-11-09 | 2010-09-29 | 아이시스 파마수티컬즈 인코포레이티드 | 7 인자 발현 조절 |
| EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| US8426378B2 (en) * | 2008-03-21 | 2013-04-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucelosides and methods for their use |
| WO2009124295A2 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| WO2009143387A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Modulation of smrt expression |
| AU2009256243A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
| EP2317847B1 (en) | 2008-07-29 | 2019-04-17 | The Board of Regents of The University of Texas System | Selective inhibition of polyglutamine protein expression |
| WO2010036696A1 (en) * | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
| NZ603603A (en) | 2008-10-15 | 2014-06-27 | Isis Pharmaceuticals Inc | Modulation of factor 11 expression |
| EP2358397B1 (en) | 2008-10-24 | 2020-01-01 | Ionis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
| US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
| US8653254B2 (en) | 2009-03-31 | 2014-02-18 | Takeda Pharmaceutical Company Limited | Process for producing nucleoside |
| WO2010120524A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| US8815586B2 (en) | 2009-04-24 | 2014-08-26 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions |
| PL3449926T3 (pl) | 2009-06-17 | 2020-06-01 | Biogen Ma Inc. | Kompozycje i sposoby modulacji składania smn2 u pacjenta |
| JPWO2010150789A1 (ja) | 2009-06-23 | 2012-12-10 | 武田薬品工業株式会社 | 核酸の合成法 |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| JP2011024434A (ja) | 2009-07-22 | 2011-02-10 | Galaxy Pharma Inc | オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー |
| EP2458005A1 (en) | 2009-07-23 | 2012-05-30 | Galaxy Pharma Inc. | Fgf21 cis-element binding substance |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| NZ714887A (en) | 2009-09-11 | 2019-07-26 | Ionis Pharmaceuticals Inc | Modulation of huntingtin expression |
| WO2011052436A1 (ja) | 2009-10-29 | 2011-05-05 | 国立大学法人大阪大学 | 架橋型人工ヌクレオシドおよびヌクレオチド |
| US20110110860A1 (en) | 2009-11-02 | 2011-05-12 | The Board Of Regents Of The University Of Texas System | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
| US8653047B2 (en) | 2010-01-08 | 2014-02-18 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011088148A1 (en) * | 2010-01-12 | 2011-07-21 | Isis Pharmaceuticals, Inc. | Modulation of transforming growth factor-beta 1 expression |
| US20120322993A1 (en) | 2010-01-20 | 2012-12-20 | Nippon Shinyaku Co., Ltd. | Phosphorylation Reagent |
| US9574191B2 (en) | 2010-02-03 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
| EP3628750A1 (en) | 2010-02-08 | 2020-04-01 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP2534248B1 (en) | 2010-02-08 | 2018-08-29 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| WO2011106689A1 (en) * | 2010-02-26 | 2011-09-01 | Isis Pharmaceuticals, Inc. | Modulation of smad3 expression |
| WO2011115817A1 (en) | 2010-03-16 | 2011-09-22 | Isis Pharmaceuticals, Inc. | Methods of preparing 2'-o-substituted purine nucleosides |
| WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP3578657B1 (en) | 2010-04-06 | 2024-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
| US9156873B2 (en) | 2010-04-28 | 2015-10-13 | Isis Pharmaceuticals, Inc. | Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom |
| KR101869570B1 (ko) | 2010-04-28 | 2018-06-20 | 아이오니스 파마수티컬즈, 인코포레이티드 | 변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물 |
| US9127033B2 (en) | 2010-04-28 | 2015-09-08 | Isis Pharmaceuticals, Inc. | 5′ modified nucleosides and oligomeric compounds prepared therefrom |
| JP5896175B2 (ja) | 2010-04-29 | 2016-03-30 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | トランスサイレチン発現の調節 |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| EP3456827A3 (en) | 2010-06-02 | 2019-05-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US8957200B2 (en) | 2010-06-07 | 2015-02-17 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US9518259B2 (en) | 2010-06-15 | 2016-12-13 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
| CN103167883B (zh) | 2010-07-19 | 2016-08-03 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
| EP2612914B1 (en) | 2010-08-31 | 2017-06-21 | Osaka University | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| US9150864B2 (en) | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| US9663783B2 (en) | 2010-11-17 | 2017-05-30 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US9127275B2 (en) | 2010-12-10 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| ES2472965T3 (es) | 2011-03-04 | 2014-07-03 | F. Hoffmann-La Roche Ag | Nuevo tipo de sondas universales para la detección de variantes gen�micas |
| WO2012135246A2 (en) | 2011-03-29 | 2012-10-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
| HUE042173T2 (hu) | 2011-04-01 | 2019-06-28 | Ionis Pharmaceuticals Inc | 'Signal transducer and activator of transcription 3' (stat3) expresszió modulálása |
| EP3460064B8 (en) | 2011-04-03 | 2024-03-20 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Efficient protein expression in vivo using modified rna (mod-rna) |
| KR101839177B1 (ko) | 2011-04-13 | 2018-03-15 | 아이오니스 파마수티컬즈, 인코포레이티드 | Ptpib 발현의 안티센스 조절 |
| WO2012145697A1 (en) | 2011-04-21 | 2012-10-26 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| PT2702155T (pt) | 2011-04-25 | 2017-04-03 | Regulus Therapeutics Inc | Compostos de microrna e métodos para modular a atividade de mir-21 |
| EP2701713B1 (en) | 2011-04-27 | 2018-02-07 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein ciii (apociii) expression |
| US9353371B2 (en) | 2011-05-02 | 2016-05-31 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
| WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| CA2838984A1 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| JP6043347B2 (ja) | 2011-06-16 | 2016-12-14 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 線維芽細胞増殖因子受容体4の発現のアンチセンス調節 |
| CN120555426A (zh) | 2011-06-21 | 2025-08-29 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
| WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| WO2013003808A1 (en) | 2011-06-29 | 2013-01-03 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
| EP2739735A2 (en) | 2011-08-01 | 2014-06-11 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| EP3922722B1 (en) | 2011-08-11 | 2023-06-28 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US9976138B2 (en) | 2011-08-29 | 2018-05-22 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| ES2796556T3 (es) | 2011-09-20 | 2020-11-27 | Ionis Pharmaceuticals Inc | Modulación antisentido de la expresión de GCGR |
| EP2771463A4 (en) | 2011-10-25 | 2015-09-09 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF GCCR EXPRESSION |
| HRP20191883T1 (hr) | 2011-11-07 | 2019-12-27 | Ionis Pharmaceuticals, Inc. | Modulacija ekspresije tmprss6 |
| US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
| ES2707232T3 (es) | 2011-12-16 | 2019-04-03 | Univ Nat Corp Tokyo Medical & Dental | Acido nucleico bicatenario quimérico |
| AU2012358238B2 (en) | 2011-12-22 | 2017-12-07 | C. Frank Bennett | Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression |
| US20150025231A1 (en) | 2012-01-11 | 2015-01-22 | Cold Spring Harbor Laboratory | Compositions and methods for modulation of ikbkap splicing |
| US20140378533A1 (en) | 2012-02-08 | 2014-12-25 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
| WO2013142514A1 (en) | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
| WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| EA030211B1 (ru) | 2012-04-25 | 2018-07-31 | Регьюлэс Терапьютикс Инк. | Соединения на основе микрорнк и способы модулирования активности mir-21 |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| WO2013177468A2 (en) | 2012-05-24 | 2013-11-28 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein(a) expression |
| EP2852606B1 (en) | 2012-05-22 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of enhancer rna mediated gene expression |
| WO2013181666A2 (en) | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
| US9828602B2 (en) | 2012-06-01 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
| DK3461895T3 (da) | 2012-06-25 | 2020-07-20 | Ionis Pharmaceuticals Inc | Modulation af ube3a-ats-ekspression |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
| US9617547B2 (en) | 2012-07-13 | 2017-04-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| WO2014018930A1 (en) | 2012-07-27 | 2014-01-30 | Isis Pharmaceuticals. Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| KR102237882B1 (ko) | 2012-08-15 | 2021-04-07 | 아이오니스 파마수티컬즈, 인코포레이티드 | 변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법 |
| EP2897633B1 (en) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
| CN104768964B (zh) | 2012-09-21 | 2017-03-29 | 国立大学法人大阪大学 | 具有胍桥的人工核苷和寡核苷酸 |
| US9523094B2 (en) | 2012-10-11 | 2016-12-20 | Ionis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
| US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US20160138014A1 (en) | 2012-10-12 | 2016-05-19 | Isis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| DK2906256T3 (en) | 2012-10-12 | 2018-11-19 | Ionis Pharmaceuticals Inc | SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF |
| EP2906258A4 (en) | 2012-10-15 | 2016-08-10 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| DK2906696T4 (da) | 2012-10-15 | 2023-02-27 | Ionis Pharmaceuticals Inc | Fremgangsmåder til modulering af c9orf72-ekspression |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| DK2920308T3 (en) | 2012-10-31 | 2019-04-01 | Ionis Pharmaceuticals Inc | cancer Treatment |
| EP2914622B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| EP2920307B1 (en) | 2012-11-15 | 2018-05-02 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CN104903448B (zh) | 2012-11-26 | 2017-07-11 | 罗氏创新中心哥本哈根有限公司 | 用于调节fgfr3的表达的组合物和方法 |
| EP2929050A1 (en) | 2012-12-10 | 2015-10-14 | AdvanDx, Inc. | Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest |
| US9695475B2 (en) | 2012-12-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Competitive modulation of microRNAs |
| JPWO2014112463A1 (ja) * | 2013-01-15 | 2017-01-19 | 国立大学法人大阪大学 | スルホンアミド構造を有するヌクレオシドおよびヌクレオチド |
| CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| DK2951305T3 (en) | 2013-01-30 | 2018-10-29 | Hoffmann La Roche | LNA oligonucleotide KULHYDRATKONJUGATER |
| DK2951191T3 (en) | 2013-01-31 | 2019-01-14 | Ionis Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS |
| CA2899924A1 (en) | 2013-02-04 | 2014-08-07 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| RU2661781C2 (ru) | 2013-02-14 | 2018-07-19 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии аполипопротеина с-iii (аросiii) у людей с дефицитом липопротеинлипазы (lpld) |
| EP2957567B1 (en) * | 2013-02-18 | 2019-06-05 | Shionogi & Co., Ltd. | Nucleoside and nucleotide, having nitrogen-containing hetercycle structure |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| EP2961853B1 (en) | 2013-02-28 | 2018-09-19 | The Board of Regents of The University of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
| CA2901983A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| EP2964785B8 (en) | 2013-03-04 | 2020-10-21 | Fry Laboratories LLC | Method and kit for characterizing microorganisms |
| JP6629716B2 (ja) | 2013-03-14 | 2020-01-15 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | タウ発現を調節するための組成物および方法 |
| MX366660B (es) | 2013-03-14 | 2019-07-18 | Alnylam Pharmaceuticals Inc | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. |
| EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
| CN115261411A (zh) | 2013-04-04 | 2022-11-01 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
| WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
| SG11201508870VA (en) | 2013-05-01 | 2015-11-27 | Isis Pharmaceuticals Inc | Compositions and methods for modulating hbv and ttr expression |
| CA2909868C (en) | 2013-05-01 | 2021-10-19 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| EA034731B1 (ru) | 2013-05-01 | 2020-03-13 | Регьюлэс Терапьютикс Инк. | Соединения на основе микрорнк и способы модулирования активности mir-122 |
| MY181888A (en) | 2013-05-22 | 2021-01-12 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
| PE20210921A1 (es) | 2013-05-22 | 2021-05-19 | Alnylam Pharmaceuticals Inc | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden |
| AU2014272526A1 (en) | 2013-05-30 | 2015-12-10 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| EP3004396B1 (en) | 2013-06-06 | 2019-10-16 | The General Hospital Corporation | Compositions for the treatment of cancer |
| US10190117B2 (en) | 2013-06-16 | 2019-01-29 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| WO2014205449A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
| US20160122761A1 (en) | 2013-06-21 | 2016-05-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US9879265B2 (en) | 2013-06-27 | 2018-01-30 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| MX375446B (es) | 2013-07-02 | 2025-03-06 | Ionis Pharmaceuticals Inc | Moduladores de receptor de hormona de crecimiento. |
| US10077236B2 (en) | 2013-07-15 | 2018-09-18 | The Regents Of The University Of California | Azacyclic constrained analogs of FTY720 |
| TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015017675A2 (en) | 2013-07-31 | 2015-02-05 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| PT3041854T (pt) | 2013-08-08 | 2020-03-05 | Scripps Research Inst | Um método para a identificação enzimática específica ao local de ácidos nucleicos in vitro pela incorporação de nucleótidos não-naturais |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| EP3038627B1 (en) | 2013-08-28 | 2020-03-04 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (pkk) expression |
| PE20160500A1 (es) | 2013-09-13 | 2016-05-21 | Ionis Pharmaceuticals Inc | Moduladores del factor del complemento b |
| US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| CN105793423A (zh) | 2013-10-02 | 2016-07-20 | 阿尔尼拉姆医药品有限公司 | 用于抑制lect2基因表达的组合物和方法 |
| AU2014331604B2 (en) | 2013-10-04 | 2021-01-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| CN112080502A (zh) | 2013-10-11 | 2020-12-15 | Ionis制药公司 | 用于调节c9orf72表达的组合物 |
| US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
| US9758546B2 (en) | 2013-10-21 | 2017-09-12 | Ionis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
| CA2928779A1 (en) | 2013-10-21 | 2015-04-30 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
| EP3077510B1 (en) | 2013-12-02 | 2020-05-06 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| IL282401B (en) | 2013-12-12 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| EP3082840B1 (en) | 2013-12-20 | 2021-03-24 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
| SI3087183T1 (sl) | 2013-12-24 | 2020-12-31 | Ionis Pharmaceuticals, Inc. | Modulacija ekspresije angiopoietin-podobnega 3 |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| AU2015217301A1 (en) | 2014-02-11 | 2016-08-25 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| US9611479B2 (en) | 2014-02-18 | 2017-04-04 | Osaka University | Crosslinked nucleoside and nucleotide |
| EP3119789B1 (en) | 2014-03-17 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
| US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
| SG11201607761UA (en) | 2014-03-19 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions for modulating ataxin 2 expression |
| SG11201608109TA (en) | 2014-04-01 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions for modulating sod-1 expression |
| US10513706B2 (en) | 2014-04-09 | 2019-12-24 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| WO2015161170A2 (en) | 2014-04-17 | 2015-10-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| WO2015164693A1 (en) | 2014-04-24 | 2015-10-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
| EP3647318B1 (en) | 2014-04-28 | 2021-06-30 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| CA2943705A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating pkk expression |
| CN111961669A (zh) | 2014-05-01 | 2020-11-20 | Ionis制药公司 | 用于调节血管生成素样蛋白3表达的组合物和方法 |
| EP4223315A3 (en) | 2014-05-01 | 2023-08-23 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
| ES2941742T3 (es) | 2014-05-01 | 2023-05-25 | Ionis Pharmaceuticals Inc | Composiciones y procedimientos para modular la expresión del factor B del complemento |
| KR20200102553A (ko) | 2014-05-01 | 2020-08-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법 |
| TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療serpinc1相關疾患之方法和組成物 |
| EA201692370A1 (ru) | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| MX2016015569A (es) | 2014-06-02 | 2017-04-25 | Children´S Medical Center Corp | Metodos y composiciones para inmunomodulacion. |
| RU2017105342A (ru) | 2014-08-07 | 2018-09-13 | Регулус Терапьютикс Инк. | НАЦЕЛИВАНИЕ НА микроРНК ПРИ РАССТРОЙСТВАХ ОБМЕНА ВЕЩЕСТВ |
| CN120591279A (zh) | 2014-08-29 | 2025-09-05 | 儿童医疗中心有限公司 | 用于治疗癌症的方法和组合物 |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| BR112017004056A2 (pt) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| US10287584B2 (en) | 2014-11-12 | 2019-05-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of COMP |
| WO2016077704A1 (en) | 2014-11-14 | 2016-05-19 | The Regents Of The University Of California | Modulation of agpat5 expression |
| HK1244843A1 (zh) | 2014-11-17 | 2018-08-17 | Alnylam Pharmaceuticals, Inc. | 载脂蛋白c3(apoc3)irna组合物及其使用方法 |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| EP4088741A1 (en) | 2014-12-08 | 2022-11-16 | The Board of Regents of the University of Texas System | Lipocationic polymers and uses thereof |
| JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
| US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
| US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
| US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| NZ733844A (en) | 2015-02-26 | 2022-07-01 | Ionis Pharmaceuticals Inc | Allele specific modulators of p23h rhodopsin |
| WO2016141236A1 (en) | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| DK3265564T3 (da) | 2015-03-03 | 2022-04-11 | Ionis Pharmaceuticals Inc | Fremgangsmåde til modulering af mecp2-ekspression |
| IL302341A (en) | 2015-03-27 | 2023-06-01 | Harvard College | Modified t cells and methods of making and using the same |
| AU2016244106B2 (en) | 2015-04-03 | 2022-05-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating TMPRSS6 expression |
| WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| SMT202000165T1 (it) | 2015-04-16 | 2020-05-08 | Ionis Pharmaceuticals Inc | Composizioni per modulare l'espressione di c9orf72 |
| EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| WO2017004261A1 (en) | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| AU2016294347B2 (en) | 2015-07-10 | 2022-07-28 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| AU2016295168B2 (en) | 2015-07-17 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| WO2017024111A1 (en) | 2015-08-04 | 2017-02-09 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
| PE20181131A1 (es) | 2015-09-02 | 2018-07-17 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS |
| JP7041616B2 (ja) | 2015-09-14 | 2022-03-24 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | リポカチオン性デンドリマーおよびその使用 |
| JP6882735B2 (ja) * | 2015-09-18 | 2021-06-02 | 国立大学法人 東京大学 | 構造強化されたmiRNA阻害剤S−TuD |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸GuNA,其製造方法,及中間體化合物 |
| JP6853539B2 (ja) | 2015-09-24 | 2021-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 合成スフィンゴ脂質様分子、薬物、これらの合成方法、および処置方法 |
| CN108513588A (zh) | 2015-09-24 | 2018-09-07 | Ionis制药公司 | Kras表达的调节剂 |
| EP3353303B1 (en) | 2015-09-25 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
| EP3359164A4 (en) | 2015-10-08 | 2019-06-12 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING THE EXPRESSION OF ANGIOTENSINOGEN |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| JP7486920B2 (ja) | 2015-11-06 | 2024-05-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | アポリポタンパク質(a)発現の調節 |
| EP4119569B1 (en) | 2015-11-06 | 2024-07-31 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
| US11058709B1 (en) | 2015-12-04 | 2021-07-13 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
| WO2017100236A1 (en) | 2015-12-07 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
| CA3006015A1 (en) | 2015-12-31 | 2017-07-06 | Ionis Pharmaceuticals, Inc. | Methods for reducing ataxin-2 expression |
| AU2017205462A1 (en) | 2016-01-05 | 2018-06-07 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
| CA3023222A1 (en) | 2016-01-26 | 2017-08-03 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11384112B2 (en) | 2016-02-17 | 2022-07-12 | Tokyo Institute Of Technology | Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide |
| CA3013797A1 (en) | 2016-03-09 | 2017-09-14 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting pmp22 expression |
| EP3429690A4 (en) | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | METHOD FOR MODULATING KEAP1 |
| WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
| US20190142856A1 (en) | 2016-04-13 | 2019-05-16 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
| MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
| AU2017260003B2 (en) | 2016-05-06 | 2019-12-05 | Astrazeneca Ab | GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof |
| EP3458032A4 (en) | 2016-05-16 | 2019-12-25 | The Board of Regents of The University of Texas System | CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS |
| JP2019518028A (ja) | 2016-06-10 | 2019-06-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法 |
| JP7075359B2 (ja) | 2016-06-14 | 2022-05-25 | バイオジェン・エムエイ・インコーポレイテッド | オリゴヌクレオチドの精製のための疎水性相互作用クロマトグラフィー |
| CA3023514A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
| WO2017223528A1 (en) | 2016-06-24 | 2017-12-28 | The Scripps Research Institute | Novel nucleoside triphosphate transporter and uses thereof |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| PL3484524T3 (pl) | 2016-07-15 | 2023-03-20 | Ionis Pharmaceuticals, Inc. | Związki i sposoby modulacji smn2 |
| KR102350647B1 (ko) | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
| US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
| CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
| MX2019009305A (es) | 2017-02-06 | 2019-09-19 | Nissan Chemical Corp | Oligonucleotido de cadena simple. |
| US11180756B2 (en) | 2017-03-09 | 2021-11-23 | Ionis Pharmaceuticals | Morpholino modified oligomeric compounds |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| EP3603648B1 (en) | 2017-03-29 | 2025-09-17 | Shionogi & Co., Ltd | Complex of nucleic acid medicine and multibranched lipid |
| MA50278A (fr) | 2017-04-18 | 2020-02-26 | Alnylam Pharmaceuticals Inc | Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb) |
| EP3599844A4 (en) | 2017-06-07 | 2021-01-13 | University of Massachusetts | ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCESSES |
| US20200163987A1 (en) | 2017-07-10 | 2020-05-28 | Genzyme Corporation | Methods and compositions for treating a bleeding event in a subject having hemophilia |
| CA3069321A1 (en) | 2017-07-11 | 2019-01-17 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| JP7277432B2 (ja) | 2017-07-13 | 2023-05-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法 |
| EP3660153A4 (en) | 2017-07-26 | 2021-04-21 | Nissan Chemical Corporation | SINGLE-STRANDED OLIGONUCLEOTIDE |
| MX2020001336A (es) | 2017-08-03 | 2020-08-20 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades autoinmunes. |
| WO2019036613A1 (en) | 2017-08-18 | 2019-02-21 | Ionis Pharmaceuticals, Inc. | MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS |
| TWI825025B (zh) | 2017-08-31 | 2023-12-11 | 日商田邊三菱製藥股份有限公司 | 包含il-33拮抗劑的子宮內膜異位症治療劑 |
| US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| US11225660B2 (en) | 2017-10-12 | 2022-01-18 | Emory University | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors |
| WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| WO2019099610A1 (en) | 2017-11-16 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| JP2021506239A (ja) | 2017-12-14 | 2021-02-22 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 複合アンチセンス化合物及びその使用 |
| CN111727252A (zh) | 2017-12-18 | 2020-09-29 | 阿尔尼拉姆医药品有限公司 | 高速泳动族盒-1(HMGB1)iRNA组合物及其使用方法 |
| WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
| JP7429642B2 (ja) | 2017-12-29 | 2024-02-08 | ザ スクリプス リサーチ インスティテュート | 非天然塩基対組成物および使用の方法 |
| KR102840298B1 (ko) | 2018-01-12 | 2025-07-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
| BR112020014011A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos |
| MA51645A (fr) | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals Inc | Modulateurs de l'expression de dnm2 |
| JP7317029B2 (ja) | 2018-02-12 | 2023-07-28 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | 修飾化合物及びその使用 |
| ES3010583T3 (en) | 2018-02-26 | 2025-04-03 | Synthorx Inc | Il-15 conjugates and uses thereof |
| WO2019169243A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
| TWI840345B (zh) | 2018-03-02 | 2024-05-01 | 美商Ionis製藥公司 | Irf4表現之調節劑 |
| CN111868244A (zh) | 2018-03-20 | 2020-10-30 | 国立大学法人东京工业大学 | 降低了毒性的反义寡核苷酸 |
| EP3768694A4 (en) | 2018-03-22 | 2021-12-29 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
| SG11202008660TA (en) | 2018-04-11 | 2020-10-29 | Ionis Pharmaceuticals Inc | Modulators of ezh2 expression |
| US12263205B2 (en) | 2018-04-30 | 2025-04-01 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| TW202016301A (zh) | 2018-05-07 | 2020-05-01 | 美商阿里拉姆製藥股份有限公司 | 肝外遞送技術 |
| UY38225A (es) | 2018-05-09 | 2019-11-29 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir de la expresión de atxn3 |
| CR20200605A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la reducción de la expresión de fxi |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原(AGT)iRNA組成物及其使用方法 |
| CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
| MX2021000922A (es) | 2018-07-25 | 2021-03-31 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de la atxn2. |
| WO2020036862A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| CN112955568B (zh) | 2018-08-15 | 2025-05-16 | Illumina公司 | 用于改善文库富集的组合物和方法 |
| TW202020157A (zh) | 2018-08-16 | 2020-06-01 | 美商艾爾妮蘭製藥公司 | 用於抑制lect2基因表現之組合物及方法 |
| CN113329739B (zh) | 2018-08-20 | 2024-06-25 | 罗贡股份有限公司 | 用于治疗scn1a脑病的靶向scn2a的反义寡核苷酸 |
| EP3620520A1 (en) | 2018-09-10 | 2020-03-11 | Universidad del Pais Vasco | Novel target to treat a metabolic disease in an individual |
| CN118667811A (zh) | 2018-09-18 | 2024-09-20 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
| TWI856973B (zh) | 2018-09-19 | 2024-10-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| CA3114396A1 (en) | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| CN113260374A (zh) | 2018-11-08 | 2021-08-13 | 新索思股份有限公司 | 白介素10缀合物及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| EA202191342A1 (ru) | 2018-11-15 | 2021-08-10 | Айонис Фармасьютикалз, Инк. | Модуляторы экспрессии irf5 |
| AU2019384181B2 (en) | 2018-11-21 | 2025-04-10 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
| EP3894559A4 (en) | 2018-12-03 | 2023-04-05 | Triplet Therapeutics, Inc. | METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY |
| CA3123617A1 (en) | 2018-12-20 | 2020-06-25 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
| BR112021012056A2 (pt) | 2018-12-20 | 2021-11-23 | Humabs Biomed Sa | Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit |
| IL316212A (en) | 2018-12-21 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of HSD17B13 expression |
| SG11202107669WA (en) | 2019-01-16 | 2021-08-30 | Genzyme Corp | Serpinc1 irna compositions and methods of use thereof |
| US11214803B2 (en) | 2019-01-31 | 2022-01-04 | Ionis Pharmaceuticals, Inc. | Modulators of YAP1 expression |
| CN114949240B (zh) | 2019-02-06 | 2025-09-23 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
| AU2020227824B2 (en) | 2019-02-27 | 2025-07-10 | Ionis Pharmaceuticals, Inc. | Modulators of MALAT1 expression |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| WO2020184700A1 (ja) | 2019-03-14 | 2020-09-17 | レナセラピューティクス株式会社 | Ihh発現を調節するための核酸複合体 |
| WO2020191177A1 (en) | 2019-03-21 | 2020-09-24 | Sudhir Agrawal | Antisense oligonucleotides for allele specificity |
| BR112021019427A2 (pt) | 2019-03-29 | 2021-11-30 | Ionis Pharmaceuticals Inc | Compostos e métodos para modular ube3a-ats |
| EP3947681A1 (en) | 2019-03-29 | 2022-02-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
| WO2020203880A1 (ja) | 2019-03-29 | 2020-10-08 | 田辺三菱製薬株式会社 | Dux4の発現を調節するための化合物、方法及び医薬組成物 |
| CN113646007B (zh) * | 2019-03-29 | 2024-08-23 | 希森美康株式会社 | 新人工核酸、其制造方法及用途 |
| AU2020268798A1 (en) | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
| US20220339256A1 (en) | 2019-05-13 | 2022-10-27 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus (hbv) infection |
| CA3138915A1 (en) | 2019-05-17 | 2020-11-26 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| HRP20250468T1 (hr) | 2019-05-28 | 2025-07-18 | Ionis Pharmaceuticals. Inc. | SPOJEVI I METODE ZA SMANJENJE POKAZATELJA FUS-a |
| CN114207129B (zh) | 2019-06-14 | 2025-07-08 | 斯克利普斯研究所 | 用于在半合成生物体中复制、转录和翻译的试剂和方法 |
| HRP20251033T1 (hr) | 2019-07-26 | 2025-10-24 | Ionis Pharmaceuticals, Inc. | Spojevi i postupci za moduliranje gfap |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Murf1を標的とする核酸医薬 |
| WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4007812A1 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof |
| EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
| WO2021030706A1 (en) | 2019-08-15 | 2021-02-18 | Synthorx, Inc. | Immuno oncology combination therapies with il-2 conjugates |
| JP2022544587A (ja) | 2019-08-15 | 2022-10-19 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | 結合修飾オリゴマー化合物及びその使用 |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| EP4025694A1 (en) | 2019-09-03 | 2022-07-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| PH12022500003A1 (en) | 2019-09-10 | 2023-04-03 | Synthorx Inc | Il-2 conjugates and methods of use to treat autoimmune diseases |
| US20220389429A1 (en) | 2019-10-04 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| JP2022551204A (ja) | 2019-10-14 | 2022-12-07 | アロ・バイオセラピューティクス・カンパニー | Cd71結合フィブロネクチンiii型ドメイン |
| WO2021074772A1 (en) | 2019-10-14 | 2021-04-22 | Astrazeneca Ab | Modulators of pnpla3 expression |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076828A1 (en) | 2019-10-18 | 2021-04-22 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
| CN115176004A (zh) | 2019-10-22 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | 补体成分C3 iRNA组合物及其使用方法 |
| CA3155921A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| BR112022006703A2 (pt) | 2019-11-04 | 2022-07-12 | Synthorx Inc | Conjugados de interleucina 10 e usos dos mesmos |
| EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| EP4055166A2 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| IL292865A (en) | 2019-11-13 | 2022-07-01 | Alnylam Pharmaceuticals Inc | Methods and preparations for the treatment of angiotensinogen-related disorder - (agt) |
| US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
| US20230041016A1 (en) | 2019-12-04 | 2023-02-09 | Athma A. PAI | Anti-slc6a1 oligonucleotides and related methods |
| CA3164599A1 (en) | 2019-12-13 | 2021-06-17 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
| TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法 |
| CN115298192A (zh) | 2020-01-15 | 2022-11-04 | 迪克纳制药公司 | 4′-o-亚甲基膦酸酯核酸及其类似物 |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| KR20220133925A (ko) | 2020-01-31 | 2022-10-05 | 가부시키가이샤산와카가쿠켄큐쇼 | Atn1의 안티센스 올리고뉴클레오티드 |
| CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
| WO2021163564A1 (en) | 2020-02-14 | 2021-08-19 | University Of Massachusetts | Oligonucleotides targeting frataxin and related methods |
| WO2021167841A1 (en) | 2020-02-18 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| WO2021174019A1 (en) | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating smn2 |
| WO2021177267A1 (ja) | 2020-03-02 | 2021-09-10 | 田辺三菱製薬株式会社 | miR-33b阻害物質による動脈瘤の予防または治療 |
| JPWO2021177418A1 (ja) | 2020-03-04 | 2021-09-10 | ||
| EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| IL296109A (en) | 2020-03-06 | 2022-11-01 | Alnylam Pharmaceuticals Inc | Ketohexokinase (khk) irna compositions and methods of use thereof |
| JP2023516748A (ja) | 2020-03-06 | 2023-04-20 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | トランスサイレチン(ttr)の発現を阻害するための組成物および方法 |
| WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| JP2023519274A (ja) | 2020-03-26 | 2023-05-10 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | コロナウイルスiRNA組成物およびその使用方法 |
| WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| AU2021252545A1 (en) | 2020-04-06 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
| WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| KR20230008078A (ko) | 2020-04-07 | 2023-01-13 | 알닐람 파마슈티칼스 인코포레이티드 | Scn9a 발현을 사일런싱하기 위한 조성물 및 방법 |
| EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
| AU2021258193A1 (en) | 2020-04-21 | 2022-11-24 | Flagship Pioneering, Inc. | Bifunctional molecules and methods of using thereof |
| CA3181400A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
| BR112022021136A2 (pt) | 2020-04-30 | 2022-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas |
| JP7738573B2 (ja) | 2020-05-01 | 2025-09-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Atxn1を調節するための化合物及び方法 |
| JP7776420B2 (ja) | 2020-05-12 | 2025-11-26 | 田辺三菱製薬株式会社 | Ataxin 3発現を調節するための化合物、方法及び医薬組成物 |
| WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
| EP4150088A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
| EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
| WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
| WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
| WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
| EP4150087A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| WO2021257782A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230242621A1 (en) | 2020-06-24 | 2023-08-03 | Vir Biotechnology, Inc. | Engineered hepatitis b virus neutralizing antibodies and uses thereof |
| IL299074A (en) | 2020-06-25 | 2023-02-01 | Synthorx Inc | Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates |
| EP4172338A4 (en) | 2020-06-29 | 2025-06-11 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING PLP1 |
| US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
| US20230272386A1 (en) | 2020-07-17 | 2023-08-31 | Mitsubishi Tanabe Pharma Corporation | Agent for preventing or treating muscular disease |
| JP2023536472A (ja) | 2020-07-28 | 2023-08-25 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Appの発現を低減するための化合物及び方法 |
| EP4192505A1 (en) | 2020-08-04 | 2023-06-14 | Dicerna Pharmaceuticals, Inc. | Systemic delivery of oligonucleotides |
| KR20230048052A (ko) | 2020-08-07 | 2023-04-10 | 아이오니스 파마수티컬즈, 인코포레이티드 | Scn2a를 조절하는 화합물 및 방법 |
| CA3189668A1 (en) | 2020-08-31 | 2022-03-03 | Do Hee Kim | Computer-implemented method for supplying a nucleic acid dataset for thedesign of oligonucleotides |
| TW202227102A (zh) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | 治療脂肪肝病之方法 |
| WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| JP7725490B2 (ja) * | 2020-09-25 | 2025-08-19 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
| EP4225917A1 (en) | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| EP4225375A1 (en) | 2020-10-09 | 2023-08-16 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
| KR20230084203A (ko) | 2020-10-09 | 2023-06-12 | 신톡스, 인크. | Il-2 접합체 및 펨브롤리주맙을 사용한 면역 종양 병용 요법 |
| WO2022087041A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| CA3196205A1 (en) | 2020-10-23 | 2022-04-28 | Floyd E. Romesberg | Reverse transcription of polynucleotides comprising unnatural nucleotides |
| CA3200595A1 (en) | 2020-11-13 | 2022-05-19 | Alnylam Pharmaceuticals, Inc. | Coagulation factor v (f5) irna compositions and methods of use thereof |
| CA3201661A1 (en) | 2020-11-18 | 2022-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
| EP4247950A1 (en) | 2020-11-18 | 2023-09-27 | Lemba BV | Umlilo antisense transcription inhibitors |
| US20240002853A1 (en) | 2020-11-23 | 2024-01-04 | Alpha Anomeric Sas | Nucleic acid duplexes |
| CA3201452A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| AU2021401424A1 (en) | 2020-12-18 | 2023-06-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating factor xii |
| EP4267732A1 (en) | 2020-12-23 | 2023-11-01 | Flagship Pioneering Innovations VI, LLC | Compositions of modified trems and uses thereof |
| WO2022147223A2 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| CA3207125A1 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| EP4274896A1 (en) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Complement component 9 (c9) irna compositions and methods of use thereof |
| IL304880A (en) | 2021-02-12 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| EP4291243A1 (en) | 2021-02-12 | 2023-12-20 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
| WO2022174101A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
| EP4298220A1 (en) | 2021-02-25 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods of use thereof |
| EP4298218A1 (en) | 2021-02-26 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| KR20230162024A (ko) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | 헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법 |
| WO2022213118A1 (en) | 2021-03-31 | 2022-10-06 | Entrada Therapeutics, Inc. | Cyclic cell penetrating peptides |
| EP4314293A1 (en) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
| WO2022214632A1 (en) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions and methods for indoor air remediation |
| WO2022221505A2 (en) | 2021-04-14 | 2022-10-20 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
| KR20240031947A (ko) | 2021-04-14 | 2024-03-08 | 에이알오 바이오테라퓨틱스 컴패니 | Fn3 도메인-시르나 접합체 및 이의 용도 |
| CA3216106A1 (en) | 2021-04-26 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
| WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| WO2022230987A1 (ja) | 2021-04-30 | 2022-11-03 | 田辺三菱製薬株式会社 | miR-33b阻害物質による筋疾患の予防又は治療 |
| EP4337261A2 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating mrna splicing |
| EP4337264A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating tissue distribution of intracellular therapeutics |
| EP4337263A1 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
| WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
| US20240263177A1 (en) | 2021-05-20 | 2024-08-08 | Korro Bio, Inc. | Methods and Compositions for Adar-Mediated Editing |
| AU2022286925A1 (en) | 2021-05-29 | 2023-12-21 | 1Globe Health Institute Llc | Short duplex dna as a novel gene silencing technology and use thereof |
| CN117858946A (zh) | 2021-05-29 | 2024-04-09 | 强新科技国际研究院 | 作为新型基因沉默技术的非对称短双链体dna及其应用 |
| EP4353266A1 (en) | 2021-05-31 | 2024-04-17 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
| WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
| EP4347823A1 (en) | 2021-06-02 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| EP4346903A1 (en) | 2021-06-03 | 2024-04-10 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| JP2024521907A (ja) | 2021-06-04 | 2024-06-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ヒト9番染色体オープンリーディングフレーム72(C9ORF72)iRNA剤組成物及びその使用方法 |
| JP2024523000A (ja) | 2021-06-08 | 2024-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | シュタルガルト病及び/又は網膜結合タンパク質4(rbp4)関連障害を治療又は予防するための組成物及び方法 |
| EP4355759A1 (en) | 2021-06-18 | 2024-04-24 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
| PE20242357A1 (es) | 2021-06-23 | 2024-12-16 | Entrada Therapeutics Inc | Compuestos antisentido y metodos para dirigirse a repeticiones cug |
| US20250034564A1 (en) | 2021-06-29 | 2025-01-30 | Korro Bio, Inc. | Methods and Compositions for ADAR-Mediated Editing |
| US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
| AU2022303164A1 (en) | 2021-06-30 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
| JP2024527584A (ja) | 2021-07-09 | 2024-07-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | CNS送達のためのBis-RNAi化合物 |
| WO2023287141A1 (ko) | 2021-07-12 | 2023-01-19 | 주식회사 씨젠 | 용기에 수용된 용액의 높이를 결정하는 방법 및 시스템 |
| EP4373934A1 (en) | 2021-07-19 | 2024-05-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| TW202421169A (zh) | 2021-07-21 | 2024-06-01 | 美商艾拉倫製藥股份有限公司 | 代謝疾患相關的標靶基因iRNA組成物及其使用方法 |
| MX2024000863A (es) | 2021-07-23 | 2024-02-09 | Alnylam Pharmaceuticals Inc | Composiciones de arni de beta-catenina (ctnnb1) y metodos de uso de estas. |
| EP4377458A1 (en) | 2021-07-29 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
| WO2023014677A1 (en) | 2021-08-03 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
| PE20241132A1 (es) | 2021-08-04 | 2024-05-24 | Alnylam Pharmaceuticals Inc | Composiciones de arni y metodos para silenciar el angiotensinogeno (agt) |
| EP4384617A1 (en) | 2021-08-13 | 2024-06-19 | Alnylam Pharmaceuticals, Inc. | Factor xii (f12) irna compositions and methods of use thereof |
| US20250034567A1 (en) | 2021-08-31 | 2025-01-30 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
| EP4396352A4 (en) | 2021-09-01 | 2025-10-01 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION |
| JP2024532464A (ja) | 2021-09-01 | 2024-09-05 | エントラーダ セラピューティクス,インコーポレイティド | デュシェンヌ型筋ジストロフィーにおいてエクソン44をスキッピングするための化合物及び方法 |
| EP4401742A2 (en) | 2021-09-17 | 2024-07-24 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
| EP4405478A1 (en) | 2021-09-20 | 2024-07-31 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| EP4408872A1 (en) | 2021-09-30 | 2024-08-07 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| WO2023056440A1 (en) | 2021-10-01 | 2023-04-06 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| CA3234887A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
| WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| JP2024541974A (ja) | 2021-10-29 | 2024-11-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ハンチンチン(HTT)iRNA剤組成物およびその使用方法 |
| IL312399A (en) | 2021-10-29 | 2024-06-01 | Alnylam Pharmaceuticals Inc | Complement factor B (CFB) iRNA compositions and methods of using them |
| WO2023080159A1 (ja) | 2021-11-02 | 2023-05-11 | レナセラピューティクス株式会社 | リガンド結合核酸複合体 |
| EP4430187A2 (en) | 2021-11-10 | 2024-09-18 | University of Rochester | Antisense oligonucleotides for modifying protein expression |
| EP4444881A2 (en) | 2021-11-10 | 2024-10-16 | University of Rochester | Gata4-targeted therapeutics for treatment of cardiac hypertrophy |
| EP4441224A1 (en) | 2021-12-03 | 2024-10-09 | Quralis Corporation | Gapmer antisense oligonucleotides with modified backbone chemistries |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| KR102731759B1 (ko) | 2021-12-10 | 2024-11-21 | 니토 보세키 가부시기가이샤 | 핵산의 대상 염기 서열 중에 있어서의 변이를 검출하기 위한 방법, 핵산의 증폭을 선택적으로 저해하는 방법, 및 이것들을 실시하기 위한 키트 |
| WO2023106190A1 (ja) | 2021-12-10 | 2023-06-15 | 日東紡績株式会社 | 二本鎖核酸の融解温度上昇化剤及びその用途 |
| KR102731760B1 (ko) | 2021-12-10 | 2024-11-21 | 니토 보세키 가부시기가이샤 | 핵산의 대상 염기 서열 중에 있어서의 변이를 검출하기 위한 방법, 핵산의 증폭을 선택적으로 저해하는 방법, 및 이것들을 실시하기 위한 키트 |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| EP4453211A1 (en) | 2021-12-22 | 2024-10-30 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| WO2023127857A1 (ja) | 2021-12-27 | 2023-07-06 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| US20250197439A1 (en) | 2022-03-18 | 2025-06-19 | Dicerna Pharmaceuticals, Inc. | Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy-nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy-nucleotide |
| US20250304957A1 (en) | 2022-05-13 | 2025-10-02 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| CN119731320A (zh) | 2022-06-10 | 2025-03-28 | 4阵营疗法公司 | 使用靶向调节rna的反义寡核苷酸调控颗粒蛋白前体表达的方法 |
| WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| EP4573198A2 (en) | 2022-08-18 | 2025-06-25 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
| EP4577650A1 (en) | 2022-08-25 | 2025-07-02 | Life Edit Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
| EP4581143A1 (en) | 2022-08-29 | 2025-07-09 | University of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
| TW202424193A (zh) | 2022-09-15 | 2024-06-16 | 美商艾拉倫製藥股份有限公司 | 第13型17β-羥基類固醇去氫酶(HSD17B13)iRNA組成物及其使用方法 |
| EP4590310A2 (en) | 2022-09-23 | 2025-07-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing mecp2 expression |
| EP4594492A1 (en) | 2022-09-30 | 2025-08-06 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
| EP4617279A1 (en) | 2022-11-10 | 2025-09-17 | Luxna Biotech Co., Ltd. | Modified nucleoside having guanidino structure in bridged part and method for producing oligonucleotide using same |
| EP4627084A1 (en) | 2022-12-01 | 2025-10-08 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2024136899A1 (en) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| AU2024217843A1 (en) | 2023-02-09 | 2025-07-31 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
| KR20250155004A (ko) | 2023-02-23 | 2025-10-29 | 유니버시티 오브 로체스터 | 폐쇄 말단 dna 가닥 분자를 제조하기 위한 제제 및 방법 |
| WO2024196937A1 (en) | 2023-03-20 | 2024-09-26 | Synthorx, Inc. | Cancer therapy with il-2 peg conjugates |
| US12383615B2 (en) | 2023-03-23 | 2025-08-12 | Carbon Biosciences, Inc. | Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods |
| WO2024196965A1 (en) | 2023-03-23 | 2024-09-26 | Carbon Biosciences, Inc. | Parvovirus compositions and related methods for gene therapy |
| TW202444908A (zh) | 2023-04-06 | 2024-11-16 | 大陸商上海舶望製藥有限公司 | 5'-膦酸酯修飾的核苷類似物及其製備的寡核苷酸 |
| AU2024254919A1 (en) | 2023-04-12 | 2025-10-30 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery of double-stranded rna agents |
| WO2024220930A2 (en) | 2023-04-20 | 2024-10-24 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024227047A2 (en) | 2023-04-28 | 2024-10-31 | Beam Therapeutics Inc. | Modified guide rna |
| WO2024233864A2 (en) | 2023-05-10 | 2024-11-14 | Dicerna Pharmaceuticals, Inc. | Galnac-conjugated rnai oligonucleotides |
| WO2024238385A2 (en) | 2023-05-12 | 2024-11-21 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| WO2024238396A1 (en) | 2023-05-12 | 2024-11-21 | Adarx Pharmaceuticals, Inc. | Nmda ligand conjugated compounds and uses thereof |
| AU2024279767A1 (en) | 2023-05-26 | 2025-12-04 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2024263694A1 (en) | 2023-06-20 | 2024-12-26 | Adarx Pharmaceuticals, Inc. | Lrrk2-modulating compositions and methods of use thereof |
| WO2025015338A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025015335A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| US20250092375A1 (en) | 2023-07-25 | 2025-03-20 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025024486A2 (en) | 2023-07-25 | 2025-01-30 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025034422A1 (en) | 2023-08-04 | 2025-02-13 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating ctnnb1-associated disorders |
| WO2025054459A1 (en) | 2023-09-08 | 2025-03-13 | Dicerna Pharmaceuticals, Inc. | Rnai oligonucleotide conjugates |
| TW202526017A (zh) | 2023-09-14 | 2025-07-01 | 美商Ionis製藥公司 | 用於減少apociii表現的化合物及方法 |
| TW202530406A (zh) | 2023-09-21 | 2025-08-01 | 美商Ionis製藥公司 | 用於抑制lpa的化合物及方法 |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025072672A2 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Slc6a19-targeting modulatory nucleic acid agents |
| WO2025072699A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Aminoglycosides for delivery of agents to the kidney |
| WO2025072713A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Polymyxins for delivery of agents to the kidney |
| WO2025076031A2 (en) | 2023-10-03 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof |
| US20250115914A1 (en) | 2023-10-04 | 2025-04-10 | Lemba Bv | Compounds for inhibition of il-1beta expression |
| WO2025074331A1 (en) | 2023-10-04 | 2025-04-10 | Lemba Bv | Compounds for inhibiting amanzi |
| WO2025080939A1 (en) | 2023-10-13 | 2025-04-17 | Ultragenyx Pharmaceutical, Inc. | Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025128853A2 (en) | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
| WO2025165891A1 (en) | 2024-01-29 | 2025-08-07 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
| WO2025178854A2 (en) | 2024-02-19 | 2025-08-28 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting cideb and related methods |
| WO2025199231A2 (en) | 2024-03-20 | 2025-09-25 | Vertex Pharmaceuticals Incorporated | Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof |
| WO2025207517A2 (en) | 2024-03-25 | 2025-10-02 | Synthorx, Inc. | Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides |
| GB202404290D0 (en) | 2024-03-26 | 2024-05-08 | Senisca Ltd | Novel oligoncleotides |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068795A1 (en) * | 2002-02-13 | 2003-08-21 | Takeshi Imanishi | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6794499B2 (en) * | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| WO1999060855A1 (en) | 1998-05-26 | 1999-12-02 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| CA2361318C (en) * | 1999-02-12 | 2008-11-25 | Sankyo Company, Limited | Novel nucleosides and oligonucleotide analogues |
-
2004
- 2004-08-25 EP EP04772134A patent/EP1661905B9/en not_active Expired - Lifetime
- 2004-08-25 US US10/569,949 patent/US7427672B2/en not_active Expired - Lifetime
- 2004-08-25 WO PCT/JP2004/012173 patent/WO2005021570A1/ja not_active Ceased
- 2004-08-25 ES ES04772134T patent/ES2382807T3/es not_active Expired - Lifetime
- 2004-08-25 AT AT04772134T patent/ATE555118T1/de active
- 2004-08-25 JP JP2005513440A patent/JP4731324B2/ja not_active Expired - Lifetime
- 2004-08-25 DK DK04772134.5T patent/DK1661905T3/da active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068795A1 (en) * | 2002-02-13 | 2003-08-21 | Takeshi Imanishi | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014051076A1 (ja) | 2012-09-28 | 2014-04-03 | 株式会社Bna | Bnaクランプ法 |
| US10253360B2 (en) | 2012-09-28 | 2019-04-09 | Bna Inc. | BNA clamp method |
| WO2018169063A1 (ja) | 2017-03-17 | 2018-09-20 | 国立大学法人千葉大学 | 構造強化されたS-TuDを用いた新規がん治療法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7427672B2 (en) | 2008-09-23 |
| ATE555118T1 (de) | 2012-05-15 |
| ES2382807T3 (es) | 2012-06-13 |
| EP1661905B9 (en) | 2012-12-19 |
| EP1661905A1 (en) | 2006-05-31 |
| EP1661905B1 (en) | 2012-04-25 |
| DK1661905T3 (da) | 2012-07-23 |
| JPWO2005021570A1 (ja) | 2007-11-01 |
| US20070167387A1 (en) | 2007-07-19 |
| WO2005021570A1 (ja) | 2005-03-10 |
| EP1661905A4 (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4731324B2 (ja) | N−o結合性架橋構造型新規人工核酸 | |
| JP5030998B2 (ja) | ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体 | |
| DK1152009T4 (en) | HIS UNKNOWN NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGS | |
| EP2495248B1 (en) | Bridged artificial nucleoside and nucleotide | |
| JP5685526B2 (ja) | ヌクレオシドの製造方法 | |
| KR20020092894A (ko) | 신규 비시클로뉴클레오시드 유연체 | |
| WO2016017422A1 (ja) | 架橋型ヌクレオシドおよびヌクレオチド | |
| CN113412268B (zh) | 5’位修饰核苷和使用其的核苷酸 | |
| JP7438546B2 (ja) | 5’位修飾ヌクレオシドおよびそれを用いたヌクレオチド | |
| Seela et al. | Phosphoramidites of base-modified 2′-deoxyinosine isosteres and solid-phase synthesis of d (GCI* CGC) oligomers containing an ambiguous base | |
| JP7678994B2 (ja) | 架橋型ヌクレオシドおよびそれを用いたヌクレオチド | |
| JP7650412B2 (ja) | 5′位修飾ヌクレオシドおよびそれを用いたヌクレオチド | |
| WO2022004388A1 (ja) | 5'位修飾ヌクレオシドおよびそれを用いたヌクレオチド | |
| JP2004182725A (ja) | 新規2’,5’−オリゴアデニル酸類縁体 | |
| JP2006063054A (ja) | 含窒素二環式糖を有する新規人工核酸 | |
| CN118946575A (zh) | 5'位修饰核苷和使用其的核苷酸 | |
| US20050176941A1 (en) | Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070801 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070912 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080124 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110405 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110419 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4731324 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |